Grail News

Illumina Takes a $1.47 Billion Charge Related to Its GRAIL Spinoff

InvestopediaJun 28 11:00 ET

Gene-sequencing Group Illumina Sees $1.47 Bn Q2 Impairment Charge Linked to Grail

Yahoo FinanceJun 28 01:02 ET

Express News | Grail Inc - Estimates That It Will Recognize a Goodwill Impairment Charge in Q2 of 2024 Equal to $888.9 Mln

ReutersJun 27 17:07 ET

Express News | Illumina Inc - Estimates That It Will Recognize an Impairment Charge for Grail Ipr&D Intangible Asset in Q2 of 2024 Equal to $420 Mln

ReutersJun 27 16:44 ET

Express News | Summit Therapeutics Appoints Jeff Huber, Transformational Google and Grail Executive, to Its Board of Directors

ReutersJun 27 16:15 ET

With a valuation of $8 billion, can the dream of Grail (GRAL.US) last after the failure of the Yanmen Pass?

After three years of struggle and tug-of-war, Illumina finally announced the divestiture of Grail on December 17th of last year. And this former unicorn also began its delayed U.S. stock market IPO four years later and officially listed on Nasdaq on June 25th this year, followed by a drama of "nearly 20% drop on the first day" for investors.

Zhitong FinanceJun 26 23:00 ET

News On GRAIL Inc. (GRALV) Now Under GRAL

News On GRAIL Inc. (GRALV) Now Under GRAL

Dow JonesJun 25 17:08 ET

Express News | Cancer Test Maker Grail's Shares Fall 12.3% to $16.34 Each on Nasdaq Debut After Opening at $18.35 per Share

ReutersJun 25 09:47 ET

Express News | GRAIL Shares Resume Trading

BenzingaJun 25 09:40 ET

Express News | Cancer Test Maker Grail Starts Trading After Spin-off From Illumina at $18.35 per Share

ReutersJun 25 09:31 ET

Cancer detection product supplier Grail (GRAL.US) will debut on Nasdaq tonight, having split from Illumina (ILMN.US).

Grail, a cancer detection product supplier split off from life science company Illumina, went public on Nasdaq on Tuesday.

Zhitong FinanceJun 25 09:27 ET

Cancer blood test developer Grail launches trading on Nasdaq, valuing it at about $7 billion

Nearly four years after first pitching for Grail Inc. (NASDAQ:GRAL), Illumina Inc. (NASDAQ:ILMN) announced Monday that it would spin off the cancer blood test developer. In July 2021, Illumina said it

BenzingaJun 25 07:17 ET

Express News | Grail Inc - Regular Way Trading on Nasdaq Global Select Market to Begin Tomorrow, June 25

ReutersJun 24 16:05 ET